瑞孚迪2025年Q3营收6.99亿美元，批准10亿美元股票回购新计划

Core Viewpoint - Revvity reported a strong performance in Q3 2025, with total revenue of $699 million, reflecting a year-over-year increase. The company has raised its full-year revenue forecast to between $2.83 billion and $2.88 billion, maintaining an organic growth expectation of 2% to 4% [2][8]. Financial Performance - Q3 2025 revenue was $699 million, compared to $684 million in the same period last year, marking a growth of approximately 2.2% [4][7]. - The GAAP operating income from continuing operations for Q3 2025 was $82 million, down from $98 million in Q3 2024, resulting in an operating margin of 11.7%, down from 14.3% year-over-year [4][7]. - Adjusted earnings per share for Q3 2025 were $1.18, a decrease from $1.28 in the same quarter last year [4][7]. Segment Performance - Life Sciences segment revenue was $343 million, a slight increase of 1% from $339 million in the previous year, with organic revenue remaining flat [4][7]. - Diagnostics segment revenue reached $356 million, up 3% from $345 million year-over-year, with organic revenue growth of 2% [4][7]. Future Outlook - The company has adjusted its full-year earnings per share forecast to between $4.90 and $5.00, reflecting confidence in continued growth despite recent foreign exchange rate fluctuations [8]. - Revvity's CEO highlighted the positive impact of key innovations and strategic partnerships, indicating a strong execution capability that is expected to drive success in 2026 and beyond [4]. Shareholder Returns - The board has approved a new two-year stock repurchase program totaling $1 billion, replacing the remaining portion of the previous buyback plan announced in October 2024 [4].